Quick answers
- What is Nogapendekin alfa inbakicept-pmln used for?
- The FDA-approved label (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., October 27, 2026) says: “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Nogapendekin alfa inbakicept-pmln?
- The “Adverse Reactions” section of the FDA label (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., October 27, 2026) begins: “The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nogapendekin alfa inbakicept-pmln have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Nogapendekin alfa inbakicept-pmln?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Nogapendekin alfa inbakicept-pmln been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Nogapendekin alfa inbakicept-pmln?
- 1 company lists prescription products of Nogapendekin alfa inbakicept-pmln in the FDA NDC Directory, including Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
What Nogapendekin alfa inbakicept-pmln is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).
— FDA label: Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (solution, intravesical), Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Nogapendekin alfa inbakicept-pmln side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. at toll-free phone 877-265-8482 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ANKTIVA in combination with TICE BCG was evaluated in Cohort A of QUILT-3.032, a single-arm, multicenter clinical study in 88 patients with BCG-unresponsive high-grade NMIBC with CIS with or without Ta/T1 papillary disease [see Clinical Studies (14)]. Patients received 400 mcg ANKTIVA with TICE BCG weekly for 6 consecutive weeks during induction and then once a week for every 3 weeks at 4, 7, 10, 13, and 19 months for patients with no or low-grade disease. Patients with persistent CIS or high-grade Ta at 3 months were eligible to receive a second induction. Patients with ongoing complete response at 25 months were eligible to receive additional instillations once a week every 3 weeks at months 25, 31, and 37. The median number of doses of ANKTIVA with BCG administered to patients was 12 (range 2 – 30) doses. The median duration of exposure to ANKTIVA with BCG was 7.1 months (range: 0.26 to 36.3 months). Serious adverse reactions occurred in 16% of patients receiving ANKTIVA with TICE BCG. Serious adverse reactions that occurred in ≥2% of patients who received ANKTIVA with TICE BCG included hematuria (3.4%). A fatal adverse reaction of cardiac arrest occurred in 1 (1.1%) patient receiving ANKTIVA with TICE BCG. Permanent discontinuation of ANKTIVA with TICE BCG due to adverse reactions occurred in 7% of patients. Adverse reactions (>2%) resulting in permanent discontinuation of ANKTIVA with TICE BCG included musculoskeletal pain (2.3%). Dosage interruptions due to adverse reactions occurred in 34% of patients receiving ANKTIVA with TICE BCG. Adverse reactions (≥5%) that resulted in interruption of ANKTIVA with TICE BCG were urinary tract infection (10%), dysuria (8%), hematuria (6%), and bladder irritation (6%). Dosage reductions due to adverse reactions were not permitted for ANKTIVA; however, dose reduction of TICE BCG was allowed for adverse reactions and occurred in 3.4% of patients. Adverse reactions (>1%) that resulted in a dose reduction of TICE BCG included urinary tract infection (2.3%), hematuria (1.1%), urinary frequency (1.1%), and bladder irritation (1.1%).
— FDA label: Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026. This is part of the section. Read the full label on DailyMed →
Nogapendekin alfa inbakicept-pmln dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
For Intravesical Use Only For induction: 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if patients have residual carcinoma in situ (CIS) and/or high-grade Ta tumors at month 3. (2.1) For maintenance: 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19.
Read more of this section
For patients with no evidence of high-grade disease at month 25 and later, additional maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37. (2.1) Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. (2.2) See full Prescribing Information for dilution and administration instructions. (2.2) 2.1 Recommended Dosage For Intravesical Use Only. Do NOT administer by subcutaneous or intravenous or intramuscular routes. For induction: ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 6 weeks. A second induction course may be administered if patients have residual carcinoma in situ (CIS) and/or high-grade Ta tumors at month 3. For maintenance: After BCG and ANKTIVA induction therapy, ANKTIVA is recommended at a dose of 400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses). For patients with no evidence of high-grade disease at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations. The recommended duration of treatment is until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months. 2.2 Preparation and Administration Preparation of Agent See BCG Prescribing Information for information on preparation and handling of BCG. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution is clear to slightly opalescent and colorless to slightly yellow. Discard the vial if visible particles are observed. Draw 0.4 mL of ANKTIVA into a small syringe and using aseptic technique add to the saline containing the BCG suspension that has been prepared following the instructions provided in the Prescribing Information for BCG. Mix the suspension gently. Using a 60-mL syringe connected to an appropriate size needle, withdraw the ANKTIVA BCG mixture to a final volume of 50 mL. If the admixture of ANKTIVA in combination with BCG is not used immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) and use within 2 hours. Unused solution of admixture should be discarded after 2 hours. Treatment The admixture of ANKTIVA in combination with BCG is instilled into the bladder via a catheter. After instillation is complete, the catheter is removed. The ANKTIVA in combination with BCG admixture is retained in the bladder for 2 hours and then voided.
— FDA label: Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026. This is part of the section. Read the full label on DailyMed →
Nogapendekin alfa inbakicept-pmln in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Systemic exposure of nogapendekin alfa inbakicept-pmln following intravesical administration of the approved dosage of ANKTIVA was below the limit of quantitation [see Clinical Pharmacology (12.3)]. Based on its mechanism of action, ANKTIVA may cause fetal harm when administered to a pregnant woman if systemic exposure occurs [see Clinical Pharmacology (12.1)]. There are no available data on ANKTIVA use in pregnant women to inform a drug-associated risk.
Read more of this section
Animal reproductive and developmental toxicity studies have not been conducted with nogapendekin alfa inbakicept-pmln. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
— FDA label: Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026. Read the full label on DailyMed →
Nogapendekin alfa inbakicept-pmln and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Females and Males of Reproductive Potential Based on its mechanism of action, ANKTIVA may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating treatment with ANKTIVA. Contraception Advise females of reproductive potential to use effective contraception during treatment with ANKTIVA and for 1 week after the last dose.
— FDA label: Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Solution |
|---|---|
| Route | Intravesical |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Anktiva |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA761336 ANKTIVA | Altor Bioscience, Llc, An Indirect Wholly-Owned Su | April 22, 2024 | 1, latest October 14, 2026 2026: Efficacy |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2682684, 2682691 |
|---|---|
| SPL set ID of the quoted label | eae31db8-3e7a-d9e0-708d-74419d1b50ff |
| FDA labels (SPL) | 1 |
| FDA applications | BLA761336 |
| Active ingredients (FDA) | NOGAPENDEKIN ALFA INBAKICEPT-PMLN |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., effective October 27, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →